Loxo Oncology CEO and COO meet with students and postdocs

Department Announcement
Posted on April 19, 2019

Josh Bilanker and Jake Van NaardenJake Van Naarden

Josh Bilenker MD (English '94) and Jake Van Naarden (Mol '06) engaged with students and postdocs on April 18 as they recounted the genesis of Loxo Oncology as part of the the Molecular Biology Industry Speaker Series. Josh (CEO) and Jake (COO) described the strategy behind Loxo's focus on genetically targeted cancer therapeutics.